YAP/TAZ-TEAD antagonist - Parabilis Medicines
Alternative Names: YAP/TAZ-TEAD antagonistLatest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator FogPharma
- Developer Harvard University; Parabilis Medicines
- Class Antineoplastics; Peptides
- Mechanism of Action Protein interaction domain and motif inhibitors; TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer